Avoiding exploitation in phase i clinical trials: More than (un)just compensation

Matt Lamkin; Carl Elliott

doi:10.1177/1073110518766008

Avoiding exploitation in phase i clinical trials: More than (un)just compensation

Matt Lamkin, Carl Elliott

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Lowering compensation to research subjects to protect them from “undue inducement” is a misguided attempt to shoehorn a concern about exploitation into the framework of autonomy. We suggest that oversight bodies should be less concerned about undue influence than about exploitation of subjects. Avoiding exploitation in human subjects research requires not only increasing compensation, but enhancing the dignity of research participation.

Original language	English (US)
Pages (from-to)	52-63
Number of pages	12
Journal	Journal of Law, Medicine and Ethics
Volume	46
Issue number	1
DOIs	https://doi.org/10.1177/1073110518766008
State	Published - Jan 1 2018

Bibliographical note

Funding Information:
We were invited to contribute a paper on themes addressed at the public conference, “The Future of Informed Consent in Research and Translational Medicine: A Century of Law, Ethics & Innovation,” which was supported by the National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), and National Cancer Institute (NCI) grant R01HG008605 on “LawSeq: Building a Sound Legal Foundation for Translating Genomics into Clinical Application” (Susan M. Wolf, Ellen Wright Clayton, Frances Lawrenz, Principal Investigators).

Publisher Copyright:
© 2018 The Author(s).

PubMed: MeSH publication types

Journal Article
Research Support, N.I.H., Extramural

Publisher link

10.1177/1073110518766008

Find It

Find It at U of M Libraries

Cite this

@article{e2998bc0f905488bb43b51e45ae129b0,

title = "Avoiding exploitation in phase i clinical trials: More than (un)just compensation",

abstract = "Lowering compensation to research subjects to protect them from “undue inducement” is a misguided attempt to shoehorn a concern about exploitation into the framework of autonomy. We suggest that oversight bodies should be less concerned about undue influence than about exploitation of subjects. Avoiding exploitation in human subjects research requires not only increasing compensation, but enhancing the dignity of research participation.",

author = "Matt Lamkin and Carl Elliott",

note = "Funding Information: We were invited to contribute a paper on themes addressed at the public conference, “The Future of Informed Consent in Research and Translational Medicine: A Century of Law, Ethics & Innovation,” which was supported by the National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), and National Cancer Institute (NCI) grant R01HG008605 on “LawSeq: Building a Sound Legal Foundation for Translating Genomics into Clinical Application” (Susan M. Wolf, Ellen Wright Clayton, Frances Lawrenz, Principal Investigators). Publisher Copyright: {\textcopyright} 2018 The Author(s).",

year = "2018",

month = jan,

day = "1",

doi = "10.1177/1073110518766008",

language = "English (US)",

volume = "46",

pages = "52--63",

journal = "Journal of Law, Medicine and Ethics",

issn = "1073-1105",

publisher = "SAGE Publications Inc.",

number = "1",

}

TY - JOUR

T1 - Avoiding exploitation in phase i clinical trials

T2 - More than (un)just compensation

AU - Lamkin, Matt

AU - Elliott, Carl

N1 - Funding Information: We were invited to contribute a paper on themes addressed at the public conference, “The Future of Informed Consent in Research and Translational Medicine: A Century of Law, Ethics & Innovation,” which was supported by the National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), and National Cancer Institute (NCI) grant R01HG008605 on “LawSeq: Building a Sound Legal Foundation for Translating Genomics into Clinical Application” (Susan M. Wolf, Ellen Wright Clayton, Frances Lawrenz, Principal Investigators). Publisher Copyright: © 2018 The Author(s).

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Lowering compensation to research subjects to protect them from “undue inducement” is a misguided attempt to shoehorn a concern about exploitation into the framework of autonomy. We suggest that oversight bodies should be less concerned about undue influence than about exploitation of subjects. Avoiding exploitation in human subjects research requires not only increasing compensation, but enhancing the dignity of research participation.

AB - Lowering compensation to research subjects to protect them from “undue inducement” is a misguided attempt to shoehorn a concern about exploitation into the framework of autonomy. We suggest that oversight bodies should be less concerned about undue influence than about exploitation of subjects. Avoiding exploitation in human subjects research requires not only increasing compensation, but enhancing the dignity of research participation.

UR - http://www.scopus.com/inward/record.url?scp=85055942960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055942960&partnerID=8YFLogxK

U2 - 10.1177/1073110518766008

DO - 10.1177/1073110518766008

M3 - Article

C2 - 30026654

AN - SCOPUS:85055942960

SN - 1073-1105

VL - 46

SP - 52

EP - 63

JO - Journal of Law, Medicine and Ethics

JF - Journal of Law, Medicine and Ethics

IS - 1

ER -

Avoiding exploitation in phase i clinical trials: More than (un)just compensation

Abstract

Bibliographical note

PubMed: MeSH publication types

Publisher link

Find It

Other files and links

Fingerprint

Cite this